The 15th Wound Congress from 21^st to 22^nd of March 2025 in Dresden, Germany

DDG-Tagung from 30^th of April to 3^rd of May 2025 Berlin, Germany

DEWU Deutscher Wundkongress from 7^th to 9^th of May 2025 in Bremen, Germany

CONTACT on the 21^st of May 2025 in Heidelberg, Germany

4^th WundD.A.CH three-country congress from 23^rd to 24^th of June 2025 in Freiburg, Germany

67^th Annual Conference of the German Society for Phlebology and Lymphology (DGPL) from 24^th to 27^th of September 2025 in Salzburg, Austria

18^th Interdisciplinary Wound Congress (IWC) on 27^th of November 2025 in Cologne, Germany

08^th Nuremberg Wound Congress (WUKO) from 04^th to 05^th of December 2025 in Nuremberg, Germany

For the press release click here

Fantastic news! The first study center for our pivotal phase III study on therapy-resistant chronic venous ulcers has now officially been activated! We are thrilled to have Mark Whiteley as the Principal Investigator, and we are excited that The Whiteley Clinic is now part of this important study.

A huge thank you to FGK Clinical Research GmbH for their invaluable support in bringing this project to life!

https://thewhiteleyclinic.co.uk/

Promising development program on stem cells in rare diseases

To the article

For the press release click here

The article outlines that this is Argentina's first study involving stem cell therapy, marking a significant milestone for the country. It also highlights the treatment of the first patient and informs that they plan to enroll at least 15 more patients in the study.

To the article

Therapies with human stem cells for chronic venous leg ulcers ("open leg").
You can find the video summary HERE.
Source: German Dermatological Society e.V. (DDG) - https://derma.de/presse

RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘

For the press release click here

RHEACELL announces "First Patient In": EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected.

For the press release click here

Professor Dr. med. Karin Scharffetter-Kochanek, Dr. Christoph Ganss and Dr. Andreas Kluth from RHEACELL received the "Kooperationspreis Wissenschaft-Wirtschaft 2022" from Ulm University.

For the press release click here (only in German)

RHEACELL receives "Partners in Progress Award" from debra of America for Epidermolysis Bullosa research.

For the press release click here

Please visit: https://www.gesundheitsindustrie-bw.de/en/article/news/innovative-stem-cell-therapy-chronic-wounds

Please visit: https://ulcus-cruris-studie.de/

It is only the second authorized "Somatic Cell Therapy Medicinal Product".

For more information click here

RHEACELL is conducting a follow-up study with highly purified stem cells for the treatment of previously incurable chronic ulcers.

For the press release click here

RHEACELL has been granted national marketing authorization in Germany (§ 4b of the German Medicinal Products Act) for its’ cell therapy product AMESANAR®, produced by TICEBA, for the use in patients with chronic wounds.

For the press release click here

The European Medicines Agency (EMA) has approved the pediatric investigation plan for our Epidermolysis Bullosa program, bringing us one step closer to filing for marketing authorization.

Based on convincing clinical results (I/IIa) in the indication of non-healing chronic venous ulcers (CVU), RHEACELL filed for national marketing authorization in Germany (special provisions governing advanced therapy medicinal products).

Heidelberg-based biopharmaceutical company demonstrates efficacy and safety of ABCB5-positive stem cells in CVU patients in clinical phase IIa trial.

Read more

Heidelberg-based biopharmaceutical company demonstrates safety and efficacy of ABCB5-positive stem cells in Phase IIa clinical trial.

Read more

Heidelberg-based biopharmaceutical company demonstrates safety and efficacy of ABCB5-positive stem cells in Phase IIa clinical trial.

Read more

Biopharma company completes three registered somatic cell therapy clinical trials for severe, chronic diseases.

Read more

The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the FDA and the European Medicines Agency) and Fast Track Designation from the FDA for the treatment of LSCD.